The Health Economics for Regenerative Medicine: How Payers Think and What That Means for Developers

C. McCabe, T. Bubela

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Health technology assessment is an increasingly important part of the path to market for new technologies. The objective analytic methods and approaches to considering evidence are radically different to those adopted by regulatory authorities such as the Food and Drug Administration and European Medicines Agency. Developers who do not understand health technology assessment risk receiving regulatory approval for their technology only to find that they cannot command the price required to make a commercial return on their investment; Prochymal being only one example of many among early regenerative medicine products. In this chapter, we describe the paradigm of health technology assessment, with a specific focus on the use of economic evaluation to inform reimbursement decisions. We then consider the challenges that regenerative medicines are likely to face in achieving reimbursement and how developers can incorporate the objective of meeting reimbursement decision criteria into the design of the research and development programme.

Original languageEnglish
Title of host publicationMesenchymal Stromal Cells
Subtitle of host publicationTranslational Pathways to Clinical Adoption
Number of pages19
ISBN (Electronic)9780128028261
ISBN (Print)9780128028407
Publication statusPublished - 1 Jan 2017
Externally publishedYes


  • cost effectiveness analysis
  • economic evaluations
  • health technology assessment
  • regenerative medicine
  • reimbursement decisions


Dive into the research topics of 'The Health Economics for Regenerative Medicine: How Payers Think and What That Means for Developers'. Together they form a unique fingerprint.

Cite this